Wednesday, August 16, 2006

Big Liberal Lie: Adult Stem Cells Have Limited Use

Embryonic Stem Cells (ESCs) have received tremendous media attention recently as the U.S. House and Senate sent two bills to the White House. A third bill died in Committee. Proponents of ESCs have enlisted the help of scientific mercenaries to perpetuate a fraud upon the gullible American public. The big lie: Adult Stem Cells (ASCs) have no real curative value. The fact that the ESC proponents don't want you to know is that ASCs are curing diseases here and now and have been doing so for decades.

Dr. David Prentice of the Family Research Council, using stricter standards of evidence, has compiled a list of 72 diseases for all types of ASCs. But three ESC advocates have directly challenged this list, publishing a letter in Science magazine. The letter claims ASC treatments are "available to treat only nine of the conditions." Even if this were true (which it's not), that would be nine more than can be claimed for ESCs. There are 1,175 clinical trials for ASCs and zero for ESCs. It is not surprising that these scientific mercenaries are at odds with the medical community as a whole.

Dr. Prentice has included ASC therapies that are approved in other countries but not yet here. More important, stem cell therapy is not a drug, and the FDA does not regulate it the same way. Some have been used successfully for decades with no one seeking or receiving federal approval. Did you know that aspirin (which the FDA recognized only for aches and pains) never went through the clinical trial process and never received formal approval by the FDA.

How can Science not know all this? The answer is simple: It does! Some members of the scientific community have become a propaganda sheet for ESC research, as well as other political causes. It should change its name to Pseudoscience. In January 2006 Science magazine had to retract two groundbreaking ESC studies that proved fraudulent. The journal wants to fund ESC research with taxpayer dollars because private investors know how unpromising it really is.

0 Comments:

Post a Comment

<< Home